AZTR | Ticker Profile - Titan Protect

AZTR

Azitra, Inc.

Healthcare · Biotechnology · ASE

$0.21

Data: 2026-05-13

✗ ETHICAL FAIL

MOAT

HIGH

Data Confidence: 100.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$4M

Total market value of the company

Trailing P/E

0.00

Forward P/E

-0.42

Based on estimated future earnings — lower means cheaper

Rev Growth

0.0%

Year-over-year revenue change

Profit Margin

0.0%

How much profit the company keeps from each dollar of revenue

ROE

-230.7%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$1.35

+540% from current price — median analyst estimate

Recommendation

NONE

Consensus view from 2 analysts covering this stock

About Azitra, Inc.

Azitra, Inc., an early-stage clinical biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and topical live biotherapeutic products to treat skin diseases in the United States. The company develops ATR-04, a genetically modified strain of S. epidermidis that is in a Phase 1/2 clinical trial for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor targeted therapy; ATR-12, a genetically modified strain of S. epidermidis, which is in a Phase 1b/2a clinical trial for treating Netherton syndrome, a skin disease; and ATR-01, a genetically modified strain of S. epidermidis that expresses an engineered recombinant human filaggrin protein, which is in the IND-enabling phase for treating ichthyosis vulgaris, a skin disease. It has a joint development agreement with Bayer for the identification and characterization of S. epidermidis strains for topical formulations. Azitra, Inc. was incorporated in 2014 and is headquartered in Branford, Connecticut.

https://azitrainc.com

Country: United States Employees: 13 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

11.9% PASS

Debt must be below 33% of total assets

Cash Ratio

58.3% FAIL

Interest-bearing cash below 33% of assets

Receivables

0.0% PASS

Receivables below 49% of assets

Revenue Purity

0.0% PASS

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

DISTRIBUTION

Smart money appears to be selling into strength — caution

Sharpe Ratio

-0.455

Returns do not compensate for the risk — negative edge

Kelly Fraction

-0.0865

No positive edge detected — the data suggests staying out

Calmar Ratio

-0.932

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-92.9%

Historical annualised return based on price data

Max Drawdown

-99.7%

Largest peak-to-trough decline — the worst it has been

HMM State

SIDEWAYS

Price consolidating — no clear directional bias

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

N/A

52W High

$2.40

91% below the year high

52W Low

$0.10

111% above the year low

Avg Volume

12,006,224

Average daily shares traded — higher means easier to buy and sell

Short Ratio

0.5

Days it would take all short sellers to cover — higher means more crowded

Short % Float

2.5%

Low short interest — limited bearish positioning

Div Yield

0.0%

Annual dividend as a percentage of the share price

EPS (TTM)

$-2.25

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

0.11

Conservative use of debt — low financial risk

Current Ratio

6.94

Strong balance sheet — comfortably covers short-term obligations

Quick Ratio

6.59

Like current ratio but excludes inventory — stricter test

Gross Margin

N/A

Revenue left after cost of goods — higher means pricing power

Operating Margin

N/A

Profit from core operations before interest and tax

Free Cash Flow

$-6,672,721

Negative — the business is spending more than it generates

Revenue (TTM)

N/A

Total revenue over the last 12 months

Net Income

$-11,814,265

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$1.70

Target Median

$1.35

Target Low

$1.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-13

Before you go